Similar articles

• t(4;14)(p16.3;q32) is strongly associated with a shorter survival in myeloma patients.

  Winkler JM, Greipp P, Fonseca R. Winkler JM, et al. Br J Haematol. 2003 Jan;120(1):170-1. doi: 10.1046/j.1365-2141.2003.03983_5.x. Br J Haematol. 2003. PMID: 12492597 No abstract available.
• The t(4;14)(p16.3;q32) is strongly associated with chromosome 13 abnormalities in both multiple myeloma and monoclonal gammopathy of undetermined significance.

  Fonseca R, Oken MM, Greipp PR; Eastern Cooperative Oncology Group Myeloma Group. Fonseca R, et al. Blood. 2001 Aug 15;98(4):1271-2. doi: 10.1182/blood.v98.4.1271. Blood. 2001. PMID: 11510469 No abstract available.
• Characterization of the t(4;14)(p16.3;q32) in the KMS-18 multiple myeloma cell line.

  Ronchetti D, Bogni S, Finelli P, Lombardi L, Otsuki T, Maiolo AT, Neri A. Ronchetti D, et al. Leukemia. 2001 May;15(5):864-5. doi: 10.1038/sj.leu.2402097. Leukemia. 2001. PMID: 11368454 No abstract available.
• The enigma of ectopic expression of FGFR3 in multiple myeloma: a critical initiating event or just a target for mutational activation during tumor progression.

  Chesi M, Bergsagel PL, Kuehl WM. Chesi M, et al. Curr Opin Hematol. 2002 Jul;9(4):288-93. doi: 10.1097/00062752-200207000-00005. Curr Opin Hematol. 2002. PMID: 12042702 Review.
• Mutations of the fibroblast growth factor receptor-3 gene in achondroplasia.

  Rousseau F, Bonaventure J, Legeai-Mallet L, Pelet A, Rozet JM, Maroteaux P, Le Merrer M, Munnich A. Rousseau F, et al. Horm Res. 1996;45(1-2):108-10. doi: 10.1159/000184768. Horm Res. 1996. PMID: 8742128 Review.